-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Tango Therapeutics (NASDAQ:TNGX)
Reviewing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Tango Therapeutics (NASDAQ:TNGX)
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) and Tango Therapeutics (NASDAQ:TNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
Earnings & Valuation
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' top-line revenue, earnings per share and valuation.
Get Aurinia Pharmaceuticals alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $45.60 million | 25.96 | -$180.97 million | ($0.83) | -10.04 |
| Tango Therapeutics | $37.04 million | 18.71 | -$58.24 million | ($1.15) | -6.83 |
Tango Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
40.4% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.3% of Tango Therapeutics shares are owned by institutional investors. 3.7% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.Volatility and Risk
Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Aurinia Pharmaceuticals and Tango Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Tango Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Aurinia Pharmaceuticals presently has a consensus price target of $12.50, indicating a potential upside of 50.06%. Tango Therapeutics has a consensus price target of $21.00, indicating a potential upside of 167.18%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Aurinia Pharmaceuticals.
Profitability
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | -89.50% | -26.03% | -22.85% |
| Tango Therapeutics | -418.63% | -32.72% | -21.48% |
Summary
Tango Therapeutics beats Aurinia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Aurinia Pharmaceuticals
(Get Rating)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
About Tango Therapeutics
(Get Rating)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) and Tango Therapeutics (NASDAQ:TNGX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.
金色医药(纳斯达克：AUPH-GET评级)和探戈治疗(纳斯达克：TNGX-GET评级)都是小盘医疗公司，但哪一家是优势投资？我们将根据这两家公司的风险、收益、盈利能力、股息、分析师建议、估值和机构所有权的强弱对它们进行比较。
Earnings & Valuation
收益与估值
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' top-line revenue, earnings per share and valuation.
此表比较了aurinia制药公司和Tango治疗公司的营收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $45.60 million | 25.96 | -$180.97 million | ($0.83) | -10.04 |
| Tango Therapeutics | $37.04 million | 18.71 | -$58.24 million | ($1.15) | -6.83 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 金银花制药 | 4,560万美元 | 25.96 | -1.8097亿美元 | ($0.83) | -10.04 |
| 探戈治疗学 | 3704万美元 | 18.71 | -5824万美元 | ($1.15) | -6.83 |
Tango Therapeutics has lower revenue, but higher earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
探戈治疗公司的收入低于金色制药公司，但收益高于金色制药公司。Auinia PharmPharmticals的市盈率低于Tango治疗公司，这表明它目前是两只股票中更负担得起的一只。
Institutional & Insider Ownership
机构与内部人持股
Volatility and Risk
波动性和风险
Aurinia Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Aurinia PharmPharmticals的贝塔系数为0.87，表明其股价的波动性比标准普尔500指数低13%。相比之下，Tango Treeutics的贝塔系数为1.78，这表明其股价的波动性比标准普尔500指数高78%。
Analyst Recommendations
分析师建议
This is a summary of recent ratings and price targets for Aurinia Pharmaceuticals and Tango Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的Auinia制药公司和Tango治疗公司最近的评级和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Tango Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 金银花制药 | 0 | 1 | 4 | 0 | 2.80 |
| 探戈治疗学 | 0 | 0 | 1 | 0 | 3.00 |
Aurinia Pharmaceuticals presently has a consensus price target of $12.50, indicating a potential upside of 50.06%. Tango Therapeutics has a consensus price target of $21.00, indicating a potential upside of 167.18%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tango Therapeutics is more favorable than Aurinia Pharmaceuticals.
Auinia PharmPharmticals目前的共识目标价为12.50美元，表明潜在涨幅为50.06%。探戈治疗公司的一致目标价为2100美元，表明潜在的上涨幅度为167.18。鉴于Tango治疗公司更强的共识评级和更高的可能上行空间，分析人士显然认为Tango治疗公司比Auinia制药公司更有利。
Profitability
盈利能力
This table compares Aurinia Pharmaceuticals and Tango Therapeutics' net margins, return on equity and return on assets.
此表比较了aurinia制药公司和Tango治疗公司的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | -89.50% | -26.03% | -22.85% |
| Tango Therapeutics | -418.63% | -32.72% | -21.48% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 金银花制药 | -89.50% | -26.03% | -22.85% |
| 探戈治疗学 | -418.63% | -32.72% | -21.48% |
Summary
摘要
Tango Therapeutics beats Aurinia Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
在两只股票之间的13个因素中，探戈治疗公司有7个因素超过了金色制药公司。
About Aurinia Pharmaceuticals
金色制药公司简介
(Get Rating)
(获取评级)
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Auinia制药公司是一家商业阶段的生物制药公司，专注于开发治疗方法并将其商业化，以治疗在美国和国际上未得到满足的医疗需求的各种疾病。该公司提供LUPKYNIS用于治疗成人活动性狼疮性肾炎。它与大冢药业有限公司有一项合作和许可协议，该公司总部设在加拿大维多利亚。
About Tango Therapeutics
关于探戈治疗公司
(Get Rating)
(获取评级)
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
探戈治疗公司是一家生物技术公司，发现和开发治疗癌症的药物。它的主要项目是TNG908，一种合成的精氨酸甲基转移酶5的致命小分子抑制剂，正在开发用于治疗甲基硫代腺苷磷酸化酶缺失的癌症。该公司还开发了泛素特异性蛋白酶1，一种用于治疗BRCA1或BRCA2突变癌症患者的抑制剂；以及针对STK11突变癌症的Target 3。探戈治疗公司与吉利德科学公司进行了战略合作，为癌症患者发现、开发一系列治疗方法并将其商业化。该公司成立于2017年，总部设在马萨诸塞州剑桥市。
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《金色医药日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对aurinia PharmPharmticals和相关公司的最新新闻和分析师评级的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧